Literature DB >> 7890684

Characterization of B61, the ligand for the Eck receptor protein-tyrosine kinase.

H Shao1, A Pandey, K S O'Shea, M Seldin, V M Dixit.   

Abstract

B61 was originally described as a novel secreted tumor necrosis factor-alpha-inducible gene product in endothelial cells (Holzman, L. B., Marks, R. M., and Dixit, V. M. (1990) Mol. Cell. Biol. 10, 5830-5838). It was recently discovered that soluble recombinant B61 could serve as a ligand for the Eck receptor protein-tyrosine kinase, a member of the Eph/Eck subfamily of receptor protein-tyrosine kinases (Bartley, T.D., Hunt, R. W., Welcher, A. A., Boyle, W. J., Parker, V. P., Lindberg, R. A., Lu, H. S., Colombero, A. M., Elliott, R. L., Guthrie, R. A., Holst, P. L., Skrine, J. D., Toso, R. J., Zhang, M., Fernandez, E., Trail, G., Yarnum, B., Yarden, Y., Hunter, T., and Fox, G. M. (1994) Nature 368, 558-560). We now show that B61 can also exist as a cell surface glycosylphosphatidyl-inositol-linked protein that is capable of activating the Eck receptor protein-tyrosine kinase, the first such report of a receptor protein-tyrosine kinase ligand that is glycosylphosphatidylinositol-linked. In addition, the expression patterns of B61 and Eck during mouse ontogeny were determined by in situ hybridization. Both were found to be highly expressed in the developing lung and gut, while Eck was preferentially expressed in the thymus. Finally, the gene for B61 was localized to a specific position on mouse chromosome 3 by interspecific back-cross analysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890684     DOI: 10.1074/jbc.270.10.5636

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  EphB6-null mutation results in compromised T cell function.

Authors:  Hongyu Luo; Guang Yu; Johanne Tremblay; Jiangping Wu
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

2.  Cellular morphogenesis in silico.

Authors:  Troy Shinbrot; Young Chun; Carlos Caicedo-Carvajal; Ramsey Foty
Journal:  Biophys J       Date:  2009-08-19       Impact factor: 4.033

3.  Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Authors:  Carla M Lema Tomé; Enzo Palma; Sara Ferluga; W Todd Lowther; Roy Hantgan; Jill Wykosky; Waldemar Debinski
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

4.  Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells.

Authors:  S J Holland; N W Gale; G D Gish; R A Roth; Z Songyang; L C Cantley; M Henkemeyer; G D Yancopoulos; T Pawson
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.

Authors:  Amanda Beauchamp; Mark O Lively; Akiva Mintz; Denise Gibo; Jill Wykosky; Waldemar Debinski
Journal:  Mol Cell Biol       Date:  2012-06-11       Impact factor: 4.272

6.  Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis.

Authors:  Charlene M Dunaway; Yoonha Hwang; Craig W Lindsley; Rebecca S Cook; Jane Y Wu; Mark Boothby; Jin Chen; Dana M Brantley-Sieders
Journal:  Mol Cell Biol       Date:  2010-12-06       Impact factor: 4.272

Review 7.  Emerging strategies for EphA2 receptor targeting for cancer therapeutics.

Authors:  Manish Tandon; Sai Vikram Vemula; Suresh K Mittal
Journal:  Expert Opin Ther Targets       Date:  2011-01       Impact factor: 6.902

Review 8.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

9.  Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.

Authors:  Nikki Cheng; Dana Brantley; Wei Bin Fang; Hua Liu; William Fanslow; Douglas Pat Cerretti; Katrin N Bussell; Alastair Reith; Dowdy Jackson; Jin Chen
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

10.  Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.

Authors:  J Wykosky; E Palma; D M Gibo; S Ringler; C P Turner; W Debinski
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.